(Reuters) - Enzon Pharmaceuticals Inc said it will suspend all clinical development activities, days after the cancer drug developer decided to explore a possible sale.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The company, in which activist investor Carl Icahn has a 13.29 percent stake, spent about $4 million last quarter on pipeline research and development and had cash, cash equivalents and marketable securities of $288.7 million as of September 30.
It will also reduce its workforce from 43 employees to about 23-28, Enzon said. Last September, it laid off about half its workforce.
The biotechnology company has two drugs in mid-stage trials and a number of others in early-stage studies.
Enzon, whose revenue mainly comes from royalty payments, will incur about $1.4 million in charges related to the reduction in force and expects to record charges in the first quarter of 2013.
Shares of Enzon, which has a market capitalization of about $200 million, closed at $4.50 on Thursday on the Nasdaq.
(Reporting by Prateek Kumar and Balaji Sridharan in Bangalore; Editing by Sreejiraj Eluvangal)
(c) Copyright Thomson Reuters 2012. Check for restrictions at: http://about.reuters.com/fulllegal.asp